Clinical Trials
Sep 19, 2026 · 1 min read · 24,259 views
Vertex aims for broad kidney disease label ahead of key readout next year
L
Liam Turner
Editorial · Sep 19, 2026
Vertex Pharmaceuticals reported that an experimental kidney disease drug called inaxaplin improved measures on a urine test in two different patient populations, raising optimism ahead of an upcoming pivotal readout. Vertex
← Previous
Roche says Carmot-acquired shot delivers Phase 2 win in overweight patients with diabetes
Next →
FDA approves ataxia-telangiectasia drug; Alkermes reports ADHD data
